|
Field
Trial End Date
|
Before
September 15, 2024
|
After
August 01, 2025
|
|
Field
Last Published
|
Before
July 01, 2024 12:58 PM
|
After
May 17, 2025 09:05 AM
|
|
Field
Intervention End Date
|
Before
September 15, 2024
|
After
July 31, 2025
|
|
Field
Primary Outcomes (Explanation)
|
Before
Quality score and binary indicators related to (i) antibiotic dispensing practices and (ii) health condition behavior & monitoring
|
After
Binary indicators related to (i) antibiotic dispensing practices
|
|
Field
Planned Number of Observations
|
Before
1,600 (4 observations per pharmacist (N=400).
|
After
Original registration: 1,600 (4 observations per pharmacist (N=400).
Revised registration: 3,325 (7 observations per pharmacist (N=475))
|
|
Field
Sample size (or number of clusters) by treatment arms
|
Before
800 (2 observations per pharmacist (N=400).
|
After
Original registration: 800 (2 observations per pharmacist (N=400).
Revised registration: 1662 (2 observations per pharmacy (N=475)).
|
|
Field
Power calculation: Minimum Detectable Effect Size for Main Outcomes
|
Before
Comparison across alternative diagnostic uncertainties: In a basic group means comparison with 80% power, a significance level of 0.05, and 0.8 unit standard deviations, the MDE is 18pp for the total sample of 1,600 observations (4 per pharmacy). (Assumption: Baseline mean of 0.3 & 1 treatment vs. 1 control group comparison).
|
After
Comparison across alternative diagnostic uncertainties: In a basic group means comparison with 80% power, a significance level of 0.05, and 0.8 unit standard deviations, the MDE is 18pp for the total sample of 1,600 observations (4 per pharmacy). (Assumption: Baseline mean of 0.3 & 1 treatment vs. 1 control group comparison).
Revised registration: MDE is 7.8pp keeping all parameters as they were except for the newly registered changes in sample size
|
|
Field
Intervention (Hidden)
|
Before
• Vignettes: Individuals will receive 4 vignettes that aim to vary patients’ symptoms to signal more/less clear underlying medical conditions. The order of the vignettes is randomized.
• Audit study: We employ an audit study in which characters portray different systems with characters being linked to diagnostically more or less clear medical conditions. The order of characters visiting pharmacies is randomized.
|
After
• Vignettes: Individuals will receive 4 vignettes that aim to vary patients’ symptoms to signal more/less clear underlying medical conditions. The order of the vignettes is randomized. Correct answers to the vignettes are financially incentivized.
• Audit study: We employ an audit study in which characters portray different systems with characters being linked to diagnostically more or less clear medical conditions. The order of characters visiting pharmacies is randomized.
|